
Bill J Gurley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/180502/publications.pdf Version: 2024-02-01



RILL I CLIDLEV

#	Article	IF	CITATIONS
1	Possible Herb-Drug Interaction Risk of Some Nutritional and Beauty Supplements on Antiretroviral Therapy in HIV Patients. Journal of Dietary Supplements, 2022, 19, 62-77.	1.4	3
2	Bulbine natalensis (currently Bulbine latifolia) and select bulbine knipholones modulate the activity of AhR, CYP1A2, CYP2B6, and P-gp. Planta Medica, 2022, 88, 975-984.	0.7	7
3	Safety and Pharmacokinetics of Intranasally Administered Heparin. Pharmaceutical Research, 2022, 39, 541-551.	1.7	3
4	Modulation of CYP3A4 and CYP2C9 activity by Bulbine natalensis and its constituents: An assessment of HDI risk of B. natalensis containing supplements. Phytomedicine, 2021, 81, 153416.	2.3	13
5	Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women. Journal of Clinical Pharmacology, 2020, 60, 209-217.	1.0	0
6	Safety and Molecular-Toxicological Implications of Cannabidiol-Rich Cannabis Extract and Methylsulfonylmethane Co-Administration. International Journal of Molecular Sciences, 2020, 21, 7808.	1.8	6
7	Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi. Journal of Dietary Supplements, 2020, 17, 599-607.	1.4	60
8	Potential Probiotic or Trigger of Gut Inflammation – The Janus-Faced Nature of Cannabidiol-Rich Cannabis Extract. Journal of Dietary Supplements, 2020, 17, 543-560.	1.4	25
9	Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches. Journal of Dietary Supplements, 2020, 17, 493-502.	1.4	23
10	Medical Foods—A Closer Look at the Menu: A Brief Review and Commentary. Clinical Therapeutics, 2020, 42, 1416-1423.	1.1	2
11	United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicology Reports, 2020, 7, 386-402.	1.6	108
12	Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration. Molecules, 2019, 24, 2256.	1.7	19
13	Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. Molecules, 2019, 24, 1694.	1.7	90
14	Decaffeinated Green Tea Extract Does Not Elicit Hepatotoxic Effects and Modulates the Gut Microbiome in Lean B6C3F1 Mice. Nutrients, 2019, 11, 776.	1.7	17
15	The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications. Journal of Clinical Psychopharmacology, 2019, 39, 462-471.	0.7	90
16	Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Proâ,,¢ (New) Tj ETQq0 0 0 Food and Chemical Toxicology, 2018, 122, 21-32.	rgBT /Ove 1.8	rlock 10 Tf 50 6
17	Follow that botanical: Challenges and recommendations for assessing absorption, distribution, metabolism and excretion of botanical dietary supplements. Food and Chemical Toxicology, 2018, 121, 194-202.	1.8	14
18	Clinically Relevant Herb-Micronutrient Interactions: When Botanicals, Minerals, and Vitamins Collide. Advances in Nutrition, 2018, 9, 524S-532S.	2.9	11

BILL J GURLEY

#	Article	IF	CITATIONS
19	"…Not Intended to Diagnose, Treat, Cure or Prevent Any Disease.―25ÂYears of Botanical Dietary Supplement Research and the Lessons Learned. Clinical Pharmacology and Therapeutics, 2018, 104, 470-483.	2.3	29
20	Practical considerations when designing and conducting clinical pharmacokinetic herb–drug interaction studies. International Journal of Pharmacokinetics, 2017, 2, 57-69.	0.5	11
21	MicroRNAs as biomarkers for liver injury: Current knowledge, challenges and future prospects. Food and Chemical Toxicology, 2017, 110, 229-239.	1.8	41
22	Safety assessment of the dietary supplement OxyELITEâ,,¢ Pro (New Formula) in inbred and outbred mouse strains. Food and Chemical Toxicology, 2017, 109, 194-209.	1.8	18
23	The Importance of Quality Specifications in Safety Assessments of Amino Acids: The Cases of L-Tryptophan and L-Citrulline. Journal of Nutrition, 2016, 146, 2643S-2651S.	1.3	12
24	Impact of <i>UGT2B17</i> Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers. Journal of Clinical Pharmacology, 2016, 56, 875-884.	1.0	17
25	Ventricular Tachycardia Precipitated by the Use of the Diet Supplement <i>Hydroxycut Gummies</i> . Hospital Pharmacy, 2015, 50, 615-618.	0.4	5
26	An ex vivo approach to botanical–drug interactions: A proof of concept study. Journal of Ethnopharmacology, 2015, 163, 149-156.	2.0	7
27	Hydrastine Pharmacokinetics and Metabolism after a Single Oral Dose of Goldenseal (<i>Hydrastis) Tj ETQq1 1</i>	0.784314 1.7	rgBT_/Overloc
28	Multi-ingredient, Caffeine-containing Dietary Supplements: History, Safety, and Efficacy. Clinical Therapeutics, 2015, 37, 275-301.	1.1	65
29	Pharmacokinetic Herb-Drug Interactions (Part 1): Origins, Mechanisms, and the Impact of Botanical Dietary Supplements. Planta Medica, 2012, 78, 1478-1489.	0.7	82
30	Pharmacokinetic Herb-Drug Interactions (Part 2): Drug Interactions Involving Popular Botanical Dietary Supplements and Their Clinical Relevance. Planta Medica, 2012, 78, 1490-1514.	0.7	129
31	Combined Effects of Ephedrine-Containing Dietary Supplements, Caffeine, and Nicotine on Morphology and Ultrastructure of Rat Hearts. Journal of Caffeine Research, 2012, 2, 123-132.	1.0	6
32	Cranberries as Antibiotics?. Archives of Internal Medicine, 2011, 171, 1279.	4.3	9
33	Validation of a liquid chromatography–tandem mass spectrometric assay for the quantitative determination of hydrastine and berberine in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 1021-1026.	1.4	30
34	Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice. European Journal of Clinical Pharmacology, 2008, 64, 293-301.	0.8	12
35	Clinical assessment of CYP2D6â€mediated herb–drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and <i>Echinacea</i> . Molecular Nutrition and Food Research, 2008, 52, 755-763.	1.5	147
36	Gauging the clinical significance of Pâ€glycoproteinâ€mediated herbâ€drug interactions: Comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Molecular Nutrition and Food Research, 2008, 52, 772-779.	1.5	124

BILL J GURLEY

#	Article	IF	CITATIONS
37	Analysis of Flavonoid Phytoestrogens in Botanical and Ephedra-Containing Dietary Supplements. Annals of Pharmacotherapy, 2007, 41, 1375-1382.	0.9	19
38	Effect of Goldenseal (Hydrastis canadensis) and Kava Kava (Piper methysticum) Supplementation on Digoxin Pharmacokinetics in Humans. Drug Metabolism and Disposition, 2007, 35, 240-245.	1.7	63
39	EFFECT OF MILK THISTLE (SILYBUM MARIANUM) AND BLACK COHOSH (CIMICIFUGA RACEMOSA) SUPPLEMENTATION ON DIGOXIN PHARMACOKINETICS IN HUMANS. Drug Metabolism and Disposition, 2006, 34, 69-74.	1.7	106
40	Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A Activity: Comparison of a Milk Thistle and Black Cohosh Product to Rifampin and Clarithromycin. Journal of Clinical Pharmacology, 2006, 46, 201-213.	1.0	96
41	Metal content of ephedra-containing dietary supplements and select botanicals. American Journal of Health-System Pharmacy, 2006, 63, 635-644.	0.5	10
42	In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clinical Pharmacology and Therapeutics, 2005, 77, 415-426.	2.3	231
43	Clinical Assessment of Effects of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly. Drugs and Aging, 2005, 22, 525-539.	1.3	210
44	ASHP Statement on the Use of Dietary Supplements. American Journal of Health-System Pharmacy, 2004, 61, 1707-1711.	0.5	51
45	In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: , , milk thistle, and saw palmetto. Clinical Pharmacology and Therapeutics, 2004, 76, 428-440.	2.3	179
46	Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. American Journal of Kidney Diseases, 2003, 42, 202-206.	2.1	65
47	Effect of a multicomponent, ephedra-containing dietary supplement (Metabolife 356) on Holter monitoring and hemostatic parameters in healthy volunteers. American Journal of Cardiology, 2003, 91, 1510-1513.	0.7	29
48	Determination of dextromethorphan and its metabolites in rat serum by liquid–liquid extraction and liquid chromatography with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 788, 261-268.	1.2	29
49	Effect of Interleukin 6 on the Hepatic Metabolism of Itraconazole and Its Metabolite Hydroxyitraconazole Using Primary Human Hepatocytes. Pharmacology, 2003, 67, 195-201.	0.9	6
50	Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 780, 129-135.	1.2	21
51	Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans*. Clinical Pharmacology and Therapeutics, 2002, 72, 276-287.	2.3	331
52	Seville (sour) Orange Juice: Synephrine Content and Cardiovascular Effects in Normotensive Adults. Journal of Clinical Pharmacology, 2001, 41, 1059-1063.	1.0	92
53	HERBAL SUPPLEMENTS: A POTENTIAL FOR DRUG INTERACTIONS IN TRANSPLANT RECIPIENTS. Transplantation, 2001, 71, 239-241.	0.5	96
54	The Tolerability of Newer Immunosuppressive Medications in a Patient with Acute Intermittent Porphyria. Journal of Clinical Pharmacology, 2001, 41, 113-115.	1.0	18

BILL J GURLEY

#	Article	IF	CITATIONS
55	St John's wort: a hidden risk for transplant patients. Progress in Transplantation, 2001, 11, 116-120.	0.4	39
56	Pretransplant evaluation of a patient with acute intermittent porphyria. Progress in Transplantation, 2001, 11, 214-216.	0.4	6
57	Comment: drug–herb interaction—AUTHOR'S REPLY. Annals of Pharmacotherapy, 2001, 35, 124-125.	0.9	0
58	Content versus label claims in ephedra-containing dietary supplements. American Journal of Health-System Pharmacy, 2000, 57, 963-969.	0.5	207
59	Drug Interaction between St. John's Wort and Cyclosporine. Annals of Pharmacotherapy, 2000, 34, 1013-1016.	0.9	216
60	Extract Versus Herb: Effect of Formulation on the Absorption Rate of Botanical Ephedrine from Dietary Supplements Containing Ephedra (Ma Huang). Therapeutic Drug Monitoring, 2000, 22, 497.	1.0	3
61	Grapefruit Juice Decreases the Systemic Availability of Itraconazole Capsules in Healthy Volunteers. Therapeutic Drug Monitoring, 1999, 21, 304.	1.0	53
62	Pharmacokinetics of cocaine and metabolites following intragastric administration to ten-day-old rat pups. Pharmaceutical Research, 1998, 15, 488-491.	1.7	0
63	Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. Journal of Pharmaceutical and Biomedical Analysis, 1998, 16, 1005-1012.	1.4	57
64	Relative bioavailability of itraconazole from an extemporaneously prepared suspension and from the marketed capsules. American Journal of Health-System Pharmacy, 1998, 55, 261-265.	0.5	3
65	Ephedrine Pharmacokinetics After the Ingestion of Nutritional Supplements Containing Ephedra sinica (ma huang). Therapeutic Drug Monitoring, 1998, 20, 439-445.	1.0	86
66	Pharmacokinetics and Cardiovascular Effects of Maâ€Huang (<i>Ephedra sinica</i>) in Normotensive Adults. Journal of Clinical Pharmacology, 1997, 37, 116-122.	1.0	123
67	Extrahepatic ischemia-reperfusion injury reduces hepatic oxidative drug metabolism as determined by serial antipyrine clearance. Pharmaceutical Research, 1997, 14, 67-72.	1.7	19
68	Comparison of Fluid Volumes with Whole Bowel Irrigation in a Simulated Overdose of Ibuprofen. Annals of Pharmacotherapy, 1995, 29, 246-250.	0.9	6
69	Stability of Flumazenil with Selected Drugs in 5% Dextrose Injection. American Journal of Health-System Pharmacy, 1993, 50, 1907-1912.	0.5	0